Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60901
Name Waldenstroem's macroglobulinemia
Definition A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma Waldenstroem's macroglobulinemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MYD88 L265P N/A Waldenstroem's macroglobulinemia not applicable detail...
Unknown unknown Umbralisib Waldenstroem's macroglobulinemia not applicable detail...
Unknown unknown Oprozomib Waldenstroem's macroglobulinemia not applicable detail...
Unknown unknown Ibrutinib Waldenstroem's macroglobulinemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT02576496 Phase I Tinostamustine Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Recruiting
NCT03085173 Phase I EGFRt/19-28z/4-1BBL CAR T cells A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Recruiting
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03364231 Phase II Umbralisib Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma Active, not recruiting
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Recruiting
NCT03498612 Phase II Pembrolizumab Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases Recruiting
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Recruiting
NCT03711578 Phase II Tenalisib Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) Active, not recruiting
NCT03740529 Phase Ib/II Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine Sulfate LOXO-305 + Rituximab + Venetoclax LOXO-305 + Venetoclax LOXO-305 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Recruiting
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Recruiting
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Recruiting
NCT04052854 Expanded access Zanubrutinib A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies Available
NCT04115059 Phase I Dasatinib Dasatinib In Waldenstrom Macroglobulinemia Recruiting
NCT04273139 Phase II Ibrutinib + Venetoclax Ibrutinib + Venetoclax in Untreated WM Recruiting
NCT04274738 Phase I Ibrutinib + X4P-001 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Recruiting